Author:
Costanzo Antonio,Russo Filomena,Galluzzo Marco,Stingeni Luca,Scuderi Roberta,Zichichi Leonardo,Papini Manuela,Di Costanzo Luisa,Conti Andrea,Burlando Martina,Chiricozzi Andrea,Gaiani Francesca Maria,Mugheddu Cristina,Musumeci Maria Letizia,Gisondi Paolo,Piaserico Stefano,Dapavo Paolo,Venturini Marina,Pagnanelli Gianluca,Amerio Paolo,Potenza Concetta,Peris Ketty,Cantoresi Franca,Trevisini Sara,Loconsole Francesco,Offidani Annamaria,Mercuri Santo Raffaele,Lora Viviana,Prignano Francesca,Bartezaghi Marta,Oliva Giovanni,Aloisi Elisabetta,Orsenigo Roberto
Abstract
Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.
Publisher
Medical Journals Sweden AB
Subject
Dermatology,General Medicine
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献